CPT 81449 Reimbursement Benchmarks & Policy

CPT code 81449 represents targeted genomic sequence analysis panels for solid organ neoplasms, focusing on RNA analysis of 5 to 50 genes. This code is central to molecular pathology and genomic sequencing, enabling laboratories to deliver precise genetic information that informs cancer diagnosis and treatment decisions. The procedure is typically performed in clinical or independent laboratory settings and is increasingly important as oncology care shifts toward personalized medicine.

Major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, provide coverage for this code, reflecting its clinical relevance and widespread adoption. Readers will gain insights into payer coverage, clinical benchmarks, and recent policy updates related to CPT 81449. The publication also explores the clinical context for the code, including its role in identifying actionable genetic alterations in solid organ tumors. Key modifiers and associated taxonomies are discussed, along with relevant ICD-10 diagnoses and related CPT codes for genomic sequencing procedures.

This summary provides a comprehensive overview of CPT 81449, highlighting its significance in cancer genomics, payer landscape, and laboratory medicine. The information is designed to support stakeholders in understanding the evolving landscape of molecular diagnostics and its impact on patient care.

CPT Code Overview

CPT 81449 is used to report targeted genomic sequence analysis panels for solid organ neoplasms, specifically focusing on RNA analysis of 5 to 50 genes. This procedure falls under molecular pathology and genomic sequencing, providing critical information for the diagnosis and management of various solid organ cancers. The typical site of service for this code is a laboratory setting, which may include independent laboratories or hospital clinical laboratories. This advanced testing supports precision medicine by identifying genetic alterations relevant to cancer treatment and prognosis.

Clinical Context

A patient with a suspected or confirmed solid organ neoplasm, such as lung, pleural, gastrointestinal, or anal cancers, is referred for advanced molecular testing. The treating oncologist requests a targeted genomic sequence analysis panel to evaluate RNA from the tumor tissue, focusing on 5 to 50 genes relevant to the neoplasm. The specimen is sent to a clinical or hospital laboratory specializing in molecular pathology. The laboratory performs the assay using next-generation sequencing techniques to identify gene expression profiles or mutations that may inform diagnosis, prognosis, or potential targeted therapies. Results are interpreted by a pathologist with expertise in molecular genetic pathology and reported back to the treating physician for clinical decision-making.

Coding Specifications

Modifiers:
- Modifier 26: Used when reporting only the professional component of the service, such as interpretation of the sequencing results by a pathologist.
- Modifier TC: Used when reporting only the technical component, which includes specimen processing, sequencing, and analysis performed by the laboratory.
Provider Taxonomies:

Taxonomy Code Specialty Name

National mean rates for CPT code 81449 show that Cigna has the highest average reimbursement at $580.87, while UnitedHealth Group and Aetna are lower at $472.27 and $466.85, respectively. The BUCA (average commercial) mean rate stands at $497.73, which is higher than Aetna and UnitedHealth Group but below Cigna. Medicare rates are not available in the input for comparison.

Rate dispersion varies significantly across payers. Cigna exhibits the widest spread, with a difference of $417.00 between its 75th and 25th percentiles, indicating substantial variability in contracted rates. UnitedHealth Group has the tightest range at $284.50, suggesting more consistent reimbursement levels. Blue Cross Blue Shield and Aetna fall in between, with ranges of $206.00 and $157.00, respectively.

The table and chart below present the full breakdown of national benchmarks for each payer, including mean rates and percentile values.

Related Diagnoses

C33–C34.92: Malignant neoplasm of trachea – malignant neoplasm of unspecified part of left bronchus or lung
- Relevant for patients with lung or tracheal cancers, where genomic sequencing may guide targeted therapy.
C38.4: Malignant neoplasm of pleura
- Used for pleural cancers, including those associated with mesothelioma, to identify actionable mutations.
C45.0: Mesothelioma of pleura
- Specific for pleural mesothelioma, where molecular profiling can inform prognosis and treatment options.
C17.0–C17.9: Malignant neoplasm of duodenum – malignant neoplasm of small intestine, unspecified
- Applied to small intestine cancers, supporting molecular characterization for personalized care.
C18.0–C19: Malignant neoplasm of cecum – malignant neoplasm of rectosigmoid junction
- Used for colorectal cancers, where sequencing may identify mutations relevant to therapy selection.
C20: Malignant neoplasm of rectum
- Relevant for rectal cancer patients, aiding in molecular diagnosis and treatment planning.
C21.1: Malignant neoplasm of anal canal
- Used for anal canal cancers, supporting targeted genomic analysis.
C21.2: Malignant neoplasm of cloacogenic zone
- Applied to rare anal cancers, where molecular testing may be beneficial.
C21.8: Malignant neoplasm of overlapping sites of rectum, anus and anal canal
- Used for tumors involving multiple sites, supporting comprehensive molecular profiling.
C7A.020–C7A.026: Malignant carcinoid tumor of the appendix – malignant carcinoid tumor of the rectum
- Relevant for neuroendocrine tumors of the gastrointestinal tract, where sequencing may identify unique genetic alterations.

Related CPT Codes

81445: Genomic sequencing panel, solid organ neoplasm, DNA (5‑50 genes)
- Used for DNA-based analysis of solid organ neoplasms, similar in scope to 81449 but focuses on DNA rather than RNA.
81450: Genomic sequencing panel, hematolymphoid neoplasm (DNA and possibly RNA, 5‑50 genes)
- Used for hematolymphoid neoplasms, analyzing DNA and possibly RNA; not specific to solid organ tumors.
81451: Genomic sequencing panel, hematolymphoid neoplasm, RNA analysis (5‑50 genes)
- Used for RNA analysis in hematolymphoid neoplasms; similar methodology to 81449 but for a different tumor type.
81455: Genomic sequencing panel, solid organ neoplasm, DNA (51+ genes)
- Used for larger DNA panels (more than 50 genes) in solid organ neoplasms; may be chosen when broader analysis is needed.
81456: Genomic sequencing panel, solid organ neoplasm, RNA (51+ genes)
- Used for larger RNA panels (more than 50 genes) in solid organ neoplasms; alternative to 81449 when more extensive gene analysis is required.

Codes 81445 and 81449 are commonly used as alternatives depending on whether DNA or RNA analysis is clinically indicated. Codes 81455 and 81456 are used when a broader panel is necessary. Codes 81450 and 81451 are specific to hematolymphoid neoplasms and are not typically used with 81449.

The table and chart below present the full breakdown of national benchmarks for each payer, including mean rates and percentile values.

OpenPayer

Summary & Overview

CPT 81449: Targeted Genomic Sequence Analysis Panel, Solid Organ Neoplasm, RNA